Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON30421
NL-OMON30421Not yet recruitingPhase 4

The METEX Study: methotrexate versus expectant management in women with ectopic pregnancy - METEX Study

Academisch Medisch Centrum0 sites72 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Enrollment
72
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •All hemodynamically stable patients >= 18 years with either an ectopic pregnancy (a visible ectopic pregnancy or an ectopic mass on transvaginal sonography) and a plateauing serum hCG concentration < 1,500 IU/L or with a Pregnancy of Unknown Location (PUL) and a plateauing serum hCG concentration < 2,000 IU/L (persisting PUL).

Exclusion Criteria

  • •Patients with a viable ectopic pregnancy, signs of tubal rupture and/or active intra abdominal bleeding or abnormalities in liver or renal function or in full blood count.

Investigators

Similar Trials

Active, not recruiting
Not Applicable
Methotrexate versus expectant management in women with ectopic pregnancy (METEX study) - METEX study
EUCTR2006-003003-39-NLAcademic Medical Center72
Completed
Not Applicable
Methotrexate versus expectant management in women with ectopic pregnancyEctopic pregnancy
ISRCTN48210491Academic Medical Center (AMC) (The Netherlands)72
Completed
Not Applicable
Methotrexate versus Expectant management in women with ectopic pregnancy.ectopic pregnancyPregnancy of unknown location (PUL)low and plateauing serum hCGmethotrexateexpectant management
NL-OMON25989Academic Medical Center, University of Amsterdam Obstetrics and Gynaecology (H4-205) Meibergdreef 9 1105 AZ AMSTERDAM THE NETHERLANDS tel: +31 20 5663693 fax: +31 20 696348972
Not yet recruiting
Unknown
Comparing methotrexate and methotrexate with methotrexate with apremilast in modifying biochemical parameters of psoriasis patients.
CTRI/2023/03/050882Anisha Biswal
Active, not recruiting
Phase 1
The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial
EUCTR2019-004148-31-NLErasmus Medisch Centrum Dept. of Pulmonology132
The METEX Study: methotrexate versus... | Clinical Trial